Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

STI Molecular Test Delivers Rapid POC Results for Treatment Guidance

By LabMedica International staff writers
Posted on 24 Dec 2025

An affordable, rapid molecular diagnostic for sexually transmitted infections (STIs) has the potential to be globally relevant, particularly in resource-limited settings where rapid, point-of-care results can significantly impact both individual treatment and antibiotic stewardship. More...

Scout Health (Santa Clara, CA, USA) is finalizing the development of STI Scout, a rapid molecular test for detecting Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) infections in under 30 minutes. The STI Scout test can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility. Designed for both point-of-care (POC) and over-the-counter (OTC) use, the test runs on the Scout Hub near-patient molecular platform, which enables earlier organism identification, resistance prediction, and better antimicrobial stewardship.

The Scout Hub test platform leverages a proprietary molecular chemistry that enables rapid detection of multiple pathogens in a single tube. This results in a test platform with orders-of-magnitude lower cost than commercially available clinical solutions while maintaining a sensitivity that can detect targets missed by rapid antigen tests. Because the system relies on minimal hardware and low-cost consumables, it can be manufactured and scaled efficiently. STI Scout uses the Scout Connect mobile app, which provides instructions, tracks results, and eventually will also allow patients to connect digitally to a healthcare provider.

Scout has been awarded additional funding from CARB-X to investigate a pilot in a low- or middle-income country, reflecting the platform's ability to extend high-quality molecular STI testing to resource and infrastructure-constrained settings. Expanding access to accurate molecular testing in settings where treatment is often empirical can support more appropriate therapy decisions and help reduce unnecessary antibiotic use.

"Cost is the number one barrier for adoption of rapid molecular testing in the US and abroad,” said Alex Jiao, PhD, CEO and Co-Founder of Scout. “COVID showed the limits of expensive, complex systems. Even with strong performance, their economics made sustained adoption impossible. Scout has focused on lowering cost through advances in chemistry and simplifying test design, enabling a platform that meets molecular performance requirements at a price point that supports a lasting, impactful solution."

Related Links:
Scout Health 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.